Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,313 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Positron Emission Tomography Clear all
Recruiting Phase 2 Interventional

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

NCT07087860
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Active, not recruiting Not applicable Interventional

Long-Term Transcutaneous Stimulation and Essential Tremor: A PET Study

NCT03778060
View directory record Official record
Conditions
Essential Tremor
Interventions
Cala TWO stimulator
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

NCT07348250
View directory record Official record
Conditions
Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
Interventions
[18F]MK-0947
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Recruiting Phase 2 Interventional

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

NCT06765317
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Interventions
Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

NCT00702143
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects

NCT03472313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 2 Interventional

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

NCT05176223
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Not applicable Interventional Results available

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

NCT01892540
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
positron emission tomography/computed tomography, PET/MRI, Position Device
Diagnostic Test · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

NCT03424525
View directory record Official record
Conditions
Bacterial Infections
Interventions
11C-Trimethoprim
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PET Imaging in Cocaine Self Administration

NCT02181491
View directory record Official record
Conditions
Cocaine Dependence
Interventions
[11C]-P943
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

NCT03113617
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

NCT00547976
View directory record Official record
Conditions
Atherosclerosis, Healthy
Interventions
[C-11]PBR28
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 1, 2026, 9:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan

NCT00351650
View directory record Official record
Conditions
Type I Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 1, 2026, 9:55 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials

NCT01546155
View directory record Official record
Conditions
Healthy Controls
Interventions
PET imaging
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 1, 2026, 9:55 AM EDT
Recruiting Phase 3 Interventional

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07217717
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
[18F]FAPI-74 PET/CT
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Cerritos, California • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

NCT01265394
View directory record Official record
Conditions
Healthy
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

NCT01207895
View directory record Official record
Conditions
Rectal Cancer
Interventions
PET imaging with [18F]-FLT, [18F]-fluorodeoxythymidine
Device · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

NCT02730546
View directory record Official record
Conditions
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
Interventions
Carboplatin, Computed Tomography, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Procedure · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Results available

PET Imaging and Bariatric Surgery

NCT00801827
View directory record Official record
Conditions
Obesity, Morbid
Interventions
F-18 (fallypride)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 1, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

NCT05635045
View directory record Official record
Conditions
Transthyretin Amyloidosis
Interventions
I 124-Evuzamitide
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 105 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 1, 2026, 9:55 AM EDT
Terminated Phase 2 Interventional

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

NCT06140407
View directory record Official record
Conditions
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
Interventions
Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 1, 2026, 9:55 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Mechanisms in Obesity

NCT05553405
View directory record Official record
Conditions
Obesity
Interventions
Intralipid Infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2033
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 1, 2026, 9:55 AM EDT